Appendix: Supplementary material [posted as supplied by author]
|
|
- James Jefferson
- 5 years ago
- Views:
Transcription
1 Appendix: Supplementary material [posted as supplied by author] Part 1 Defining a recorded 10 year CVD risk score All available recorded 10-year risk scores in the CPRD were identified during the study period. There were circumstances where more than one risk score per patient was recorded in the same day, which is believed to be due to a GP taking several blood pressure recordings and carrying out more than one calculation on that day. If this was the case, and there was a mixture of coronary heart disease risk scores and cardiovascular disease risk score, then the cardiovascular disease risk score(s) was used. If there were still more than one recorded risk score, and they fell in conflicting risk score categories, then none of the patients records were used as we were unable to identify which category the true score belonged to. If there were several recorded risk scores on the same day, in the same risk score category, this risk score category was assigned to the patient. For primary analyses assessing the initiation of statins for primary prevention, we restricted to patients with a risk score 20% because such patients were eligible for statin treatment both before and after the July 2014 NICE guideline changes. A patient could also have more than one CVD risk score and therefore more than one opportunity to initiate a statin for primary prevention (in which case they would contribute to more than one monthly data point). Part 2 Defining the grace period for initiation analysis in patients prescribed statins for secondary prevention We identified all incident cardiovascular events between January 2011 and October 2013 and calculated the length of time between date of cardiovascular event and incident statin prescription. We identified that 59% of all patients with an incident cardiovascular event in this period had been prescribed a statin in primary care within 60 days of the event. Taking into account that defining an extremely long grace period could result in identifying statin prescriptions which were not related to the cardiovascular event in question, we deemed this an adequate proportion of patients initiating statins, and hence defined the grace period to be 60 days. Part 3 Defining the length of statin prescription For all statin prescriptions, if the daily dose was of an unreasonable value (greater than 4 or 0 tablets per day), the median of one tablet per day was imputed. If the quantity of tablets prescribed was of an unreasonable value (greater than 300 or less than 7 tablets), then the median of 28 was imputed. In the event where a patient had more than one statin prescription on the same day, the length of all prescriptions were summed to calculate the overall prescription length. 1
2 Part 4 Google search term trend analytics using the search term `statin side effects 1 The month with the highest search volume within the specified period volume has a search volume index of 100 and all other months are assigned an index with relation to this. Part 5 - Negative control analysis detail: drugs used for glaucoma Two analyses were carried out: one for cessation and one for initiation analyses. For the cessation analysis, for each calendar month, we identified all individuals aged >40 years and in receipt of a glaucoma drug prescription that ended within that calendar month. Prescription end dates were calculated as 28 days after the prescription start date. A patient could be included in more than one monthly cohort if they had multiple prescriptions ending during the study period. The grace period was calculated using the same criteria as the preliminary analysis for the main cessation analysis. All glaucoma prescriptions between January 2011 and October 2013 were identified and the length of time between the end of prescription and the start of a new prescription was calculated. We identified that 90% of prescriptions were followed up with a new prescription within 46 days of the initial prescription ending, which was then used as the grace period. For the initiation negative control analysis, we calculated the proportion of all patients under follow-up in the CPRD that month who had an incident glaucoma drug prescription. For both analyses, we used the same statistical methods used for primary analyses and evaluated a step and trend change after the exposure time period, in comparison to before. Part 6 - Public health impact calculation The excess number of patients that stopped statins in the six month period following our exposure time period was This was calculated by comparing the monthly modelled proportions of patients stopping within this six month period using our post-hoc analyses, with the hypothetical monthly proportions in the same period under the counterfactual scenario of no changes after exposure, for both primary and secondary prevention. Each monthly proportion difference was then multiplied by the total number of patients in the denominator that month. These totals were then summed over the six month period for both primary and secondary prevention models to calculate the total number of excess stoppers. We then estimated the number of excess CVD events among these patients over the following 10-years, based on the assumptionss outlined below, and finally we scaled this up to reflect the likely impact in the full UK population. 2
3 1) CVD risk There were 84,884 distinct patients that stopped statins and were originally prescribed for primary prevention in the 6 months following the exposure time period. 34,997 of these had previously had a recorded 10-year CVD risk score in CPRD, and the median 10-year risk was at the upper end of the 10-20% 10 year CVD risk category. Hence, we decided to assume a 10-year CVD risk of 20% among patients who stopped statins used for primary prevention. Patients with a prior CVD event are usually considered at clinically high risk of a further CVD event, based on clinical trial data in secondary prevention populations where five year CVD event rates of over 20% are regularly reported 28, 29. For a conservative estimate, we therefore also assumed a 10-year CVD risk of 20% to the number of patients that stopped statins used for secondary prevention. 2) Risk reduction attributed to statins Using results from the CTT, the relative risk reduction of a major vascular event in patients prescribed statins in comparison to a non-statin prescribed control was 19% (95% CI: 12%,23%), for all patients with a 5 year major vascular event risk of 20% and <30%. 3) Proportion that would have stopped later, regardless of the media coverage A proportion of patients stopping due to the media coverage would have stopped therapy at some later point in their subsequent 10-year follow-up, regardless of the media coverage. To provide an estimate of the proportion of patients stopping statins within a 10-year period, we followed up a cohort of patients with a statin prescription ending in March 2003, for 10 years. We defined an event as no further prescriptions for at least a year following the end of a prescription, or death within a year following end of their last prescription. Patients were censored if they left CPRD within a year of the end of their last prescription, or after 10 years if they were still being prescribed statins at that date. Kaplan-Meier methods were then used to analyse time to statin cessation, and at 10 years the survival function (estimated proportion remaining alive and on a statin) was Among patients identified as stopping or dying during follow-up, the median time to event was 5.21 years. Final calculation of excess CVD events due to media coverage The 10-year CVD risk and statin-associated risk reduction were then applied to the total number of excess stoppers. Based on the analysis described above, we assumed that even in the absence of the media coverage, only 51.1%% of these patients would have continued statins for the full 10 years, and the remaining 48.9% would have received only 50% of the protection (based on median of 5.21 years use out of 10). The final estimated number of CVD events attributed to the media coverage among CPRD patients was then scaled up to the total population of the UK (CPRD covers 6.9% of the total UK population) to calculate the excess number of CVD events within the UK attributed to the media controversy. Post cessation restart rates The above calculation assumed that those stopping their statin never restarted. However, Zhang et al. recently reported that 65.9% of patients who stopped statins, without a statin-related event, had another prescription over the subsequent 12 months. To provide a second more conservative estimate allowing for this, we therefore repeated the above calculation assuming that 65.9% of the excess patients who stopped statin therapy restarted quickly and had no loss of protection. 3
4 Part 7 Primary analyses evaluating a trend change in the proportion of patients initiating and stopping statin therapy for primary and secondary prevention of CVD after the exposure time period (October 2013 March 2014) A - Initiation analysis for primary prevention p<0.001 Proportion of Patients Stopping/Initiating B - Initiation analysis for secondary prevention p=0.411 C - Cessation analysis for primary prevention p= D - Cessation analysis for secondary prevention p=0.155 Calendar Month 1 An interrupted time series analysis using a generalised linear model with a binomial error structure was used for all models, with break points at the beginning and end of the exposure time period. Models allowed for a change in trend of the proportion of patients initiating/stopping statin therapy. P-values relate to the Wald test comparing the trend of initiating/stopping statins before the exposure period, to the trend after. Graphs A and B: Denominators are the patients with the opportunity to initiate statin therapy each month within the study period, and numerators are the patients that did initiate statin therapy following the prior indication. Graphs C and D: Denominators are the patients with a statin prescription ending each month within the study period, and numerators are patients that did not renew that prescription and hence were defined as stopping. 4
5 Part 8 Post-hoc analysis evaluating a step and trend change in the proportion of patients stopping statin therapy for primary and secondary prevention of CVD after the exposure time period (October 2013 March 2014) Proportion of patients stopping A - Cessation analysis for primary prevention B - Cessation analysis for secondary prevention Calendar Month An interrupted time series analysis using a generalised linear model with a binomial error structure was used for all models, with break points at the beginning and end of the exposure time period. Models allowed for both a change in level and a change in trend of the proportion of patients stopping statin therapy. Denominators are the patients with a statin prescription ending each month within the study period, and numerators are patients that did not renew that prescription and hence stopped. In all graphs, the solid lines and shaded confidence intervals relate to linear predictions of the log odds and 95% confidence 5
6 Part 9 Control analysis evaluating a step change in the proportion of patients initiating and stopping glaucoma therapy after the exposure time period (October 2013 March 2014) Proportion of Patients Stopping/Initiating A - Initiation analysis for control OR 1 = 0.97(0.89,1.05) B - Cessation analysis for control OR 1 = 1.05(0.98,1.12) Calendar Month 1 An interrupted time series analysis using a generalised linear model with a binomial error structure was used for all models, with break points at the beginning and end of the exposure time period. Models allowed for a change in level of the proportion of patients initiating/stopping statin therapy. ORs therefore relate to the relative change in the odds of initiating/stopping statins after the exposure time period, in comparison to what we expected based on pre-exposure predictions. Graph A: Denominators are the all patients under follow up in the CPRD each month within the study period, and numerators are the patients that initiated glaucoma therapy. Graph B: Denominators are the patients with a glaucoma prescription ending each month within the study period, and numerators are patients that did not renew that prescription and hence were defined as stopping. In all graphs, the solid lines and shaded confidence intervals relate to linear predictions of the log odds and 95% 6
7 Part 10 Control analysis evaluating a trend change in the proportion of patients initiating and stopping glaucoma therapy after the exposure time period (October 2013 March 2014) Proportion of Patients Stopping/Initiating A - Initiation analysis for control p=0.086 B - Cessation analysis for control p=0.853 Calendar Month 1 An interrupted time series analysis using a generalised linear model with a binomial error structure was used for all models, with break points at the beginning and end of the exposure time period. Models allowed for a change in trend of the proportion of patients initiating/stopping statin therapy P-values relate to the Wald test comparing the trend of initiating/stopping statins before the exposure period, to the trend after. Graph A: Denominators are the all patients under follow up in the CPRD each month within the study period, and numerators are the patients that initiated glaucoma therapy. Graph B: Denominators are the patients with a glaucoma prescription ending each month within the study period, and numerators are patients that did not renew that prescription and hence were defined as stopping. 7
8 Part 11 ISAC Protocol Impact on initiation and cessation of statins amidst the media interest in the side effects of lipid lowering therapy prior to the 2014 NICE lipid modification guidelines Lay Summary In July 2014, the National Institute for Healthcare and Clinical Excellence (NICE) amended their guidelines for statin therapy for the primary prevention of cardiovascular disease, lowering the cardiovascular risk threshold for which a patient should be recommended statins from 20% to 10% ten year risk. In the context of debate surrounding these impending changes, Abramson et al. published a paper in October 2013 claiming that prescribing statins to people with a low risk of cardiovascular disease would increase the number of adverse events, without providing overall health benefit. A high volume of media coverage followed. We would like to examine if media coverage around adverse side effects impacted the initiation and cessation of statin prescribing in patients at high risk of a cardiovascular event in the UK. We will do this by calculating the percentage of patients starting and stopping statins for both primary and secondary prevention at monthly intervals from We will then investigate changes in the proportion of patients starting and stopping at key time points. Background Statins are lipid lowering drugs that reduce the risk of cardiovascular disease [1]. In the 12 months preceding March million statins prescriptions were dispensed in primary care in England at a cost of million [2]. In July 2014, NICE published amended guidelines in relation to patients that should be recommended a statin prescription [3]. The amendments stated that patients whose 10-year risk of cardiovascular disease is over 10% should be prescribed statins. Previous guidelines published in 2007 recommended a risk cut off point of 20%. The new guidelines also recommended the exclusive use of the QRISK2 method for calculating cardiovascular disease risk and continued to recommend the prescription of statins to all patients with existing cardiovascular disease. There was much controversy prior to the publication of these guideline changes, especially since there was found to be a wide variation between practices in statin prescribing to patients at higher risk (> 20%) of cardiovascular disease [4]. For example, Abramson et al. published a paper in the BMJ in October 2013 claiming that broadening the recommendations on cholesterol lowering guidelines to include statin therapy for low risk individuals will unnecessarily increase the incidence of adverse effects, without providing overall health benefit [5]. More specifically, Abramson et al included a claim (later the subject of a correction) that side-effects occurred in approximately 18-20% of patients using statins. This created concern as it was thought that high risk patients may have stopped statin therapy as a result of these comments, even though the controversy was stimulated by arguments about treating low risk patients. A high volume of media interest followed. 8
9 Although there have been anecdotal suggestions from a questionnaire by the British Cardiovascular Society [6], there is no quantitative evidence as to whether this controversy around potential side effects of statins has impacted the initiation and cessation of the drug within UK general practice. Objective, specific aims and rationale Objective The overall objective is to estimate changes over time in initiation and cessation of lipid-lowering therapy for both primary and secondary prevention, and the impact of media interest in side effects. Aims 1. To evaluate time trends in initiation of statins in patients with and without incident cardiovascular events from , and whether the proportion initiating has been affected by media controversy about side effects; 2. To evaluate time trends in cessation of statins in patients with and without existing cardiovascular disease from , and whether the proportion stopping has been affected by media controversy about side effects. 3. To investigate whether any such media effects differ by patient characteristics, cardiovascular risk factors, or overall cardiovascular risk. 4. To estimate the public health impact of any changes in statin usage patterns due to the media controversy. Rationale and public health importance Following the controversy surrounding potential side effects of statins, it is possible that patients eligible for statins have declined the drug, and that some existing users have stopped treatment. As statins have been proven to reduce the risk of cardiovascular disease, such patients are at increased risk of a cardiovascular event. Study type Hypothesis testing. The null hypothesis is that the controversy in the media following the comment by Abramson et al that the statin side effect rate is 18-20% did not affect the initiation and cessation of statin therapy in UK general practice between 2011 and Study design Interrupted time series analysis of trends of initiation and cessation of statins. Linked Data No linked data are required for this study. 9
10 Study populations Initiation analyses: Registered patients aged 40 and over with documented eligibility to receive a statin for primary (i.e. cardiovascular risk of >20% over ten years) or secondary prevention of cardiovascular disease. Cessation analyses: Registered patients aged 40 and over receiving statins for primary or secondary prevention of cardiovascular disease. Exposures, outcomes and covariates Exposures We aim to describe trends in both initiation and cessation of statins over time. We also specifically want to investigate whether there are significant changes in trends of initiation and cessation surrounding the following time points: Primary time exposure Media coverage regarding the side effects of statins between November 2013 and March 2014 The aforementioned article by Abramson et al discussing the adverse side effects of statins was published in the BMJ on 22/10/2013. We have also identified, using google trends analytics, that peak public interest in the side effects of statins was within March 2014 [Fig. 1]. This is based on the google search term statin side effects and corresponds to the volume of people using this search term. We therefore intend to investigate the trends in initiation and cessation of statins before, during and after the period between these two events (October 2013 March 2014). We decided on this exposure time period as controversy surrounding statin side effects first came into public interest at the time of the Abramson BMJ paper. This information was then publically available with interest reaching its peak within March 2014 when most major national news media (including the BBC and national newspapers) covered the subject. Therefore, all patients with a vested interest in statins are likely to have been exposed to the information at some point between November 2013 and March 2014 inclusive. We will subsequently carry out a sensitivity analysis shifting the exposure time period, hence assessing a time lag in the patients reacting to the media coverage. Figure 1: Google analytics search term trends using the search term 'statin side effects' 10
11 Outcomes Initiation of statins will be defined as a first recorded statin prescription at least 1 year after start of follow-up in CPRD. All patients whose first prescription is up to a year after registration will be excluded as this could be a continuation of an existing prescription from a previous GP Cessation of statins among those on a statin at a particular time point will be defined as having no further statin prescriptions within a specified grace period (identified in preliminary analyses defined below) following the end date of last prescription. Key Definitions Cardiovascular event An event relating to coronary heart disease (myocardial infarction, angina and revascularisation procedures), cerebrovascular disease (stroke, transient ischaemic attack), or peripheral vascular disease (abdominal aortic aneurism and intermittent claudication). Codes relating to incident events and preexisting conditions will be identified, based on codelists developed for the CALIBER project (Cardiovascular Disease Research Using Linked Bespoke Studies and Electronic Records, Cardiovascular risk scores All available methods of risk score calculation will be identified. A pre-specified code list for cardiovascular risk score events is available in appendix 1. To minimise the effect of actual guideline changes on our results (and hence focus on the effects of media controversy), we will restrict to those with calculated risk scores of over 20%, or a Read term which indicates a ten year cardiovascular risk of 20% or more; such patients were eligible for statin treatment both before and after the July 2014 guideline changes. Statins Prescriptions in relation to all forms of statin will be identified. The duration and prescription end date of each prescription will be calculated using the number of tablets prescribed and daily dosage instructions; where this information is unavailable, we will use the median prescription duration. The end date will be calculated as the date of prescription plus the number of days drug supply. Data/Statistical Analysis All data will be analysed using Stata v13 (StataCorp, Texas) Preliminary analysis 1. Analysis of prescription gaps to inform operational definition of continuous statin use: For all statin prescriptions from Jan 2011 to Oct 2013 (so that these preliminary analyses aren t affected by the 11
12 media controversy) we will calculate the gap between the end of one prescription and the start of the next, and plot the distribution of gaps. We will use this analysis (without reference to the main time trends of interest) to inform the gap, or grace period that should be used to deem a prescription continuous. Any prescription gaps exceeding our defined grace period will be defined as a cessation in statin prescription, with the date of cessation being the end date of the most recent prescription. 2. Preliminary analysis to inform definition of initiation for secondary prevention: It is likely that a patient is admitted to hospital after a cardiovascular event. Further to this, it is likely that they are administered statins whilst in hospital and given statins on discharge. These hospital-based prescriptions would not be picked up in the primary care data we are using, so in evaluating statin initiation among these patients, there is a need to allow for a delay until the patient has the opportunity to receive their first prescription from a GP. In order to understand how long a delay is necessary, we will plot the distribution of the number of days between incident cardiovascular events and first statin prescription in primary care for all incident cardiovascular events between Jan 2011 and October We will use this to define a sensible length of time that patients should be followed up to determine if they initiated statins in primary care after an incident cardiovascular event. Aim 1 Initiation of statins (i) Initiation for secondary prevention For each calendar month between 2011 and 2015, we will identify all patients experiencing a first cardiovascular event during the given calendar month (denominator), and we will calculate the percentage of these patients initiating a statin based on receiving a first statin prescription within a pre-specified length of time since the cardiovascular event (as determined by the preliminary analyses described above, Figure 2). Thus, for each calendar month, we will generate a single proportion of patients that initiate statins as per the guidelines, which will then be plotted by calendar month from All patients whose CPRD follow-up ends during the pre-specified time period used to capture statin initiation will be excluded, since it would be impossible to reliably ascertain initiation for these individuals. Figure 2: Explanation of cohort for initiation of statins in secondary prevention Modelling changes in proportion of patients initiating statins by calendar time We will perform an interrupted time series analysis, using segmented linear regression, of proportion of patients initiating statins each month. We will divide time into segments before, during and after the exposure time period (October 2013-March 2014, Figure 3) [7,8]. We will then explore a change in trend of 12
13 initiation at the beginning and end of the exposure time period by testing for a change in slope at these time points. We will also explore a change in trend comparing the time period before exposure to the time period after exposure. As a secondary analysis, we will also explore a step-change in initiation by testing for a change in level. We will include a term in the regression model for the lagged residuals, to account for autocorrelation (observations closer together in time series tend to be more similar than observations further apart), and we will assess for seasonality, adjusting accordingly if necessary [9]. Figure 3: Illustration of model for initiation time trends in relation to key time points Proportion initiating Before trend Transition period trend After trend November 2013 (publication of Abramson et al) March 2014 (peak media interest) Calendar time (ii) Initiation for primary prevention For each calendar month between 2011 and 2015, we will identify all patients with a calculated score of 20% ten year cardiovascular risk, with no previous cardiovascular events, during the given calendar month (denominator). We will calculate the percentage of these patients initiating a statin within 1 month. The 20% risk threshold will be used because eligibility for primary prevention among this group has not changed since 2011, so the pre- and post-exposure comparison will not be complicated by the 2014 guideline change. All further analyses will be carried out as in Aim 1 (i), but patients with a cardiovascular event within the one month follow up, which pre-dates any statin prescription, will also be excluded as these patients will be identified in Aim 1 (i). We will also explore effect modification by age, sex and cardiovascular risk in stratified secondary analyses. Aim 2 Cessation of statins (i) Cessation among those taking statins for secondary prevention 13
14 For each calendar month between 2011 and 2015, we will identify (as the denominator) all patients with existing cardiovascular disease and a statin prescription which ends during that month (where end date is the date of last prescription plus number of days drug supply); this represents all patients with an opportunity to stop their statin that month according to our definition of stopping (namely not renewing a prescription that has run out, within a pre-defined grace period). If a patient has several prescriptions which end in the same month, then their latest prescription end date will be used. The numerator will be the number of patients that stop taking statins, defined as no further prescriptions within the grace period defined in our preliminary analyses (Fig 4). The proportion of patients stopping will then be plotted by calendar month from All results will be stratified by length of time prescribed to a statin without stopping (<12 months, months, >36 months). Figure 4: Explanation of cohort for cessation of statins in secondary prevention Modelling changes in proportion of patients that stop taking statins by calendar time We will then use segmented linear regression for the interrupted time series analysis, using the same exposure time period and approach as in Aim 1. (ii) Cessation among those taking statins for primary prevention For each calendar month between 2011 and 2015, we will identify all patients without a previous cardiovascular event and a statin prescription with an end date within that month (denominator). Cessation of statin prescribing will be defined as in Aim 2(i). Percentage of patients that stop taking statins will then be plotted by calendar month from and all further analyses will be carried out as in Aim 2 (i). However, patients with a cardiovascular event during the predefined grace period will also be excluded from the denominator. Control Analysis In order to assess if a possible significant step-change or change in trend in initiation and persistence to statins is due to exposure of peak public interest in statin side effects, we will run the same analyses using a 14
15 negative control. For initiation and persistence in secondary prevention we will use patients prescribed beta blockers after a diagnosis of myocardial infarction, and for initiation and persistence in primary prevention we will use patients exposed to an ACE inhibitor or angiotensin 2 receptor blocker as a first line treatment for newly diagnosed hypertension. The same primary and secondary time exposure points will be used. We have no reason to expect any significant changes in usage patterns for these drugs at the prespecified exposure time points. Aim 3 effect modification To explore whether statin initiation/cessation are more or less affected by media controversy among key subgroups, we will also conduct stratified analyses by age group, sex, risk score stratum, diabetes status, and treated hypertension status, as well as duration of statin use (for cessation analyses). Aim 4 public health impact To estimate the potential public health impact of changes in statin initiation and prescribing trends, we will compare the observed proportion of individuals initiating and stopping a statin in each month after March 2014, with the hypothetical proportions of people initiating/stopping in the same period under the counterfactual scenario of no changes in trends at the two time points of interest (i.e. simply projecting the modelled before trend line [see Figure 3] forward), thus estimating the proportion of people that may have declined to initiate, or stopped a statin, due to the media controversy, under the assumption of causality. We will combine this calculation with national cardiovascular disease/mortality event rates and known statin efficacy estimates from the Cholesterol Treatment Trialists Collaboration [10] to estimate the impact of the changes in statin usage patterns on number of cardiovascular disease events and deaths. For simplicity, this analysis will initially assume that those declining to initiate in a given calendar month do not go on to initiate later, and that those stopping do not later restart. Since this is a strong assumption, we will also examine actual statin usage patterns among those who do not immediately initiate, or who cease therapy, and if a substantial proportion start (or restart) therapy later, we will repeat the impact analysis allowing for this. Sample size/power calculation The following sample size calculations are based on an extract of 1,000,000 patients from the CPRD, scaled up to represent the 14,000,000 patients in the full sample. Based on our inclusion and exclusion criteria, the individual data points estimating monthly proportions of patients initiating and ceasing statin therapy will include 1,148 patients eligible for the statin initiation analyses, and 146,622 patients eligible for the cessation analyses, leading to high precision of the individual data points, with confidence intervals ranging from +0.20% to +2.89%. For the interrupted time series analysis we will have at least 48 data points (monthly initiation and cessation proportion estimates), with 10 data points after our exposure time period (using the July 2015 CPRD build) and each data point will have at least 336 outcome events. Using a power calculation for the comparison of Poisson counts across two groups, we will have 90% power at a 95% confidence level to detect a rate ratio of at least 1.07 when comparing the rate of either initiation or cessation before and after the exposure time period 15
16 Patient/User group involvement We have not engaged with patients or user-groups in the development of this protocol. Limitations of the study design, data sources and analytic methods Missing data There is likely to be missingness in the variables used to report cardiovascular risk score, even when there is a Read code which implies a calculation has been made. Feasibility analyses suggest the missingness will be approximately 11%. Entries will be excluded if they have a missing risk score calculation and the risk stratum cannot be determined from the Read term. Random error The study will be conducted among all currently registered patient fulfilling the exclusion and exclusion criteria. We estimate between 1,100 and 250,000 acceptable patients for each calendar-month-specific cohort, so random error will be minimal. Bias and generalisability GP practices are self-selecting with respect to their contribution to CPRD, however those practices contributing are thought to be broadly representative of the UK population. Very few patients within contributing practices refuse to participate at an individual level and this is not thought to bias the results in any way. Therefore our analyses should reflect the distribution of statin prescriptions among the UK population, and should be generalisable. The analyses of statin initiation require a minimum period of follow-up to assess whether a statin was started. It is possible that those not initiating a statin and therefore without the protection offered by this treatment, may be less likely to reach the end of this minimum follow-up period, due to a higher risk of death. This would result in statin initiation rates being overestimated. We do not think this is a major limitation because the minimum follow-up periods are short (e.g. 1 month for the primary prevention analysis), and even if overall initiation rates are overestimated, this should not affect the main calendar time trends of interest. Plans for disseminating and communicating results The study findings will be submitted for publication in peer-reviewed scientific journals, and will be presented at appropriate conferences and other meetings. We will engage fully in opportunities to communicate our results to the general public, including via the media. 16
17 ISAC References 1. Taylor, F, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, : p. Cd National Institute for Health and Clinical Excellence. NICE implementation uptake report: statins for the prevention of cardiovascular events. NICE technology appraisal : London 3. National Institute for Health and Care Excellence (NICE). Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE clinical guideline : London. 4. van Staa, T-P, et al. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment? Heart 2013;0: Abramson, et al. Should people at low risk of cardiovascular disease take a statin? BMJ :f BCS Statins and the Media Survey Results. British Cardiovascular Society Wagner, AK, et al. Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics Morgan, OW, et al. Interrupted Time-Series Analysis of Regulations to Reduce Paracetamol (Acetaminophen) Poisoning. PLoS Medicine e Bhaskaran, K, et al. Time series regression studies in environmental epidemiology. International Journal of Epidemiology. 2013;42: Cholesterol Treatment Trialists' (CTT) Collaborator. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380(9841):
18 ISAC Appendices Appendix 1 Cardiovascular risk score code list 18
19 Amendments to original protocol (changes approved by ISAC in December 2015) 1) We focussed on comparing changes in the level and trend of statin initiation/cessation after the exposure period compared with before for our primary analysis, rather than estimating changes at the beginning and end of the exposure period, which would have been driven by the imprecisely estimated trend in the interim period (estimated using only 4 data points) 2) We used drugs prescribed for glaucoma as an exposure for the negative control analysis. This analysis was changed from our original negative control exposures of beta-blockers/ace inhibitors as we believed there to be too large an overlap in the use of statins and ACE inhibitors/betablockers meaning that changes in prescribing of each could be related. Like statins, glaucoma drugs are prescribed to those at high risk of disease as a preventative measure and are typically intended to be continued for life after initiation, but they have the advantage (for our purposes) of a completely unrelated indication. 3) As well as adjusting for seasonality and autocorrelation, we scaled standard errors using the square root of the Pearson chi-squared based dispersion scalar to account for over dispersion in all main analyses. 4) We conducted a post-hoc cessation analysis which separated post-exposure time into two six month periods. This decision was made because the observed data points in the analyses for cessation in primary and secondary prevention suggested an initial change after the exposure period that later attenuated, and executing these post-hoc analyses allowed us to assess if levels of cessation returned to a level similar to pre-exposure after six months. These post-hoc analyses were a more accurate representation of the trends in cessation, and so were used to estimate public health impact. 5) Another tool we used to explore the initial change in cessation for primary and secondary prevention, which later attenuated, was to carry out post-hoc analyses investigating both a step change in level and a trend change simultaneously. This allowed us to determine a monthly rate at which cessation fell after the initial increase in level. 6) To investigate an observed decrease in the number of patients receiving a cardiovascular disease risk score of 20% following the exposure time period (the denominator for initiation analyses in primary prevention), we explored the proportion of patients with any recorded 10 year CVD risk score in the whole CPRD population each month within our study period. We then investigated whether patients were categorised as at very high ( 30%), high (20-30%%), intermediate (10-20%) or low (<10%) risk of CVD. 7) We conducted a secondary negative control analysis using an alternative exposure time period of 12 months earlier than our original exposure time period. This was because we had no reason to expect any changes in prescribing trends around this time. 8) As well as applying cardiovascular disease event rates and known statin efficacy estimates to the public health impact, we also corrected for the proportion of patients likely to have stopped statin therapy over 10 years regardless of the media controversy (estimated from historical CPRD data), and published post-cessation restart rates. 19
Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data
open access Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data Anthony Matthews, 1 Emily Herrett, 1 Antonio Gasparrini, 2 Tjeerd Van Staa,
More informationDiscontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationTechnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394 NICE 2017. All rights reserved. Subject to
More informationESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study
ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards
More informationCochrane Pregnancy and Childbirth Group Methodological Guidelines
Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationCost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia
Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ). Following NCPE assessment of the applicant
More informationRecent developments for combining evidence within evidence streams: bias-adjusted meta-analysis
EFSA/EBTC Colloquium, 25 October 2017 Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis Julian Higgins University of Bristol 1 Introduction to concepts Standard
More informationNICE Indicator Programme. Consultation on proposed amendments to current QOF indicators
NICE Indicator Programme Consultation on proposed amendments to current QOF s Consultation dates: 18 July to 1 August 2018 This document outlines proposed amendments to a small number of QOF s in the diabetes
More informationTrends and Variations in General Medical Services Indicators for Coronary Heart Disease: Analysis of QRESEARCH Data
Trends and Variations in General Medical Services Indicators for Coronary Heart Disease: Analysis of QRESEARCH Data Authors: Professor Julia Hippisley-Cox Professor Mike Pringle Professor of Clinical Epidemiology
More informationBias and confounding special issues. Outline for evaluation of bias
EPIDEMIOLOGI BIAS special issues and discussion of paper April 2009 Søren Friis Institut for Epidemiologisk Kræftforskning Kræftens Bekæmpelse AGENDA Bias and confounding special issues Confounding by
More informationImproved Transparency in Key Operational Decisions in Real World Evidence
PharmaSUG 2018 - Paper RW-06 Improved Transparency in Key Operational Decisions in Real World Evidence Rebecca Levin, Irene Cosmatos, Jamie Reifsnyder United BioSource Corp. ABSTRACT The joint International
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationHowever, if instead, CHD risk is plotted on a doubling scale (as in slide 2) then there is a
Slides 1 and 2: These two illustrative slides (based on notionaldata) were used in my presentation to Dr Godlee at our meeting on 2 December 2013 to show that, if the risk of coronary disease (CHD) is
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationArticles. Funding Medical Research Council, National Institute for Health Research, and Wellcome Trust.
Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1 5 million people Eleni Rapsomaniki, Adam Timmis, Julie George,
More informationDronedarone for the treatment of non-permanent atrial fibrillation
Dronedarone for the treatment of non-permanent atrial Issued: August 2010 last modified: December 2012 guidance.nice.org.uk/ta197 NICE has accredited the process used by the Centre for Health Technology
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationRepeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group
Repeat ischaemic heart disease audit of primary care patients (2002-2003): Comparisons by age, sex and ethnic group Baseline-repeat ischaemic heart disease audit of primary care patients: a comparison
More informationTime Series Analysis for selected clinical indicators from the Quality and Outcomes Framework
Time Series Analysis for selected clinical indicators from the Quality and Outcomes Framework 21-26 Title Document Type Time Series Analysis for selected clinical indicators from the Quality and Outcomes
More informationSaving Lives, Saving Families: The health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH)
1 Saving Lives, Saving Families: The health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH) Economics Chapter: Estimating the benefits from treatment and increasing
More informationTable S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis
SUPPLEMENTARY MATERIAL TEXT Text S1. Multiple imputation TABLES Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis Table S2. List of drugs included as immunosuppressant
More informationImproving Medical Statistics and Interpretation of Clinical Trials
Improving Medical Statistics and Interpretation of Clinical Trials 1 ALLHAT Trial & ALLHAT Meta-Analysis Critique Table of Contents ALLHAT Trial Critique- Overview p 2-4 Critique Of The Flawed Meta-Analysis
More informationBlood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ
1 Blood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ 2016.033440 Dear Editor, Editorial Committee and Reviewers Thank you for your appreciation
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationRESEARCH. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database Julia Hippisley-Cox, professor of clinical epidemiology and general practice,
More informationpatients actual drug exposure for every single-day of contribution to monthly cohorts, either before or
SUPPLEMENTAL MATERIAL Methods Monthly cohorts and exposure Exposure to generic or brand-name drugs were captured at an individual level, reflecting each patients actual drug exposure for every single-day
More informationINTERVAL trial Statistical analysis plan for principal paper
INTERVAL trial Statistical analysis plan for principal paper 8 January 2016, final agreed version Compiled by Simon Thompson, on behalf of the INTERVAL Trial Steering Committee 1. Aim The purpose of this
More informationCoronary Heart Disease
Coronary Heart Disease This document is a final specification of the PRIMIS Comparative Analysis Service (CAS) MIQUEST query set to enable analyses in support of the NSF for CHD. The specification has
More informationComments from AstraZeneca UK Ltd
13 June 2007 NICE HTA: Ezetimibe for the treatment of primary (heterozygous familial and nonfamilial) hypercholesterolemia Appraisal Consultation Document (ACD) Many thanks for providing the ACD for the
More informationthe standard deviation (SD) is a measure of how much dispersion exists from the mean SD = square root (variance)
Normal distribution The normal distribution is also known as the Gaussian distribution or 'bell-shaped' distribution. It describes the spread of many biological and clinical measurements Properties of
More informationTechnology appraisal guidance Published: 28 November 2012 nice.org.uk/guidance/ta267
Ivabradine adine for treating chronic heart failure Technology appraisal guidance Published: 28 November 2012 nice.org.uk/guidance/ta267 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationAntidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database
open access Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database Carol Coupland, 1 Trevor Hill, 1 Richard Morriss, 2 Michael Moore, 3
More informationRESEARCH. Katrina Wilcox Hagberg, 1 Hozefa A Divan, 2 Rebecca Persson, 1 J Curtis Nickel, 3 Susan S Jick 1. open access
open access Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
More informationUK Liver Transplant Audit
November 2012 UK Liver Transplant Audit In patients who received a Liver Transplant between 1 st March 1994 and 31 st March 2012 ANNUAL REPORT Advisory Group for National Specialised Services Prepared
More informationRESEARCH. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study
Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study Julia Hippisley-Cox, professor of clinical epidemiology and general practice,
More informationGetting serious about preventing cardiovascular disease
Getting serious about preventing cardiovascular disease Southwark s Experience Professor Kevin Fenton Director of Health and Wellbeing, London Borough of Southwark February 2018 Twitter: @ProfKevinFenton
More informationDiabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care
open access Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care Julia Hippisley-Cox, Carol Coupland Division of Primary Care, University
More informationEffect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case control analysis
752 CARDIOVASCULAR MEDICINE Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case control analysis J Hippisley-Cox, C Coupland... Heart
More informationReflection paper on assessment of cardiovascular safety profile of medicinal products
25 February 2016 EMA/CHMP/50549/2015 Committee for Medicinal Products for Human Use (CHMP) Reflection paper on assessment of cardiovascular safety profile of medicinal products Draft agreed by Cardiovascular
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Epidemiology for the uninitiated
Clinical epidemiologist have one foot in clinical care and the other in clinical practice research. As clinical epidemiologists we apply a wide array of scientific principles, strategies and tactics to
More informationCoronary heart disease and stroke
4 Coronary heart disease and stroke Overview of cardiovascular disease Cardiovascular disease (CVD), also called circulatory disease, describes a group of diseases which are caused by blockage or rupture
More information2. Morbidity. Incidence
2. Morbidity This chapter reports on country-level estimates of incidence, case fatality and prevalence of the following conditions: myocardial infarction (heart attack), stroke, angina and heart failure.
More informationImpact of Eliminating Medicaid Adult Dental Coverage in California on Emergency. Department Use for Dental Problems
Impact of Eliminating Medicaid Adult Dental Coverage in California on Emergency Department Use for Dental Problems Introduction: Oral health is an integral part of overall well-being. Apart from having
More informationDevelopment and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study
Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study Julia Hippisley-Cox, 1,2 Carol Coupland 1 1 Division of Primary Care, University
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationUNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator
UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator QOF indicator area: Hypertension Under 80 Potential output:
More informationStatistical Analysis Plan
The BALANCED Anaesthesia Study A prospective, randomised clinical trial of two levels of anaesthetic depth on patient outcome after major surgery Protocol Amendment Date: November 2012 Statistical Analysis
More informationRisk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies
Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies Nicola J Adderley, Krishnarajah Nirantharakumar, Tom Marshall Institute
More informationSection A: Clarification on effectiveness data. Licensed population
Section A: Clarification on effectiveness data Licensed population A1: priority question Please provide the information depicted in the following table for each of the subgroups listed below (i.e., 7 tables
More informationJae Jin An, Ph.D. Michael B. Nichol, Ph.D.
IMPACT OF MULTIPLE MEDICATION COMPLIANCE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE II DIABETES AND COMORBID HYPERTENSION CONTROLLING FOR ENDOGENEITY BIAS Jae Jin An, Ph.D. Michael B. Nichol, Ph.D.
More informationASPIRIN AND VASCULAR DISEASE
ASPIRIN AND VASCULAR DISEASE SUMMARY Aspirin is an effective antiplatelet agent for patients with cardiovascular and cerebrovascular disease. Incidence of adverse effects and drug interactions increases
More informationAN INDEPENDENT VALIDATION OF QRISK ON THE THIN DATABASE
AN INDEPENDENT VALIDATION OF QRISK ON THE THIN DATABASE Dr Gary S. Collins Professor Douglas G. Altman Centre for Statistics in Medicine University of Oxford TABLE OF CONTENTS LIST OF TABLES... 3 LIST
More informationThe Economic Burden of Hypercholesterolaemia
The Economic Burden of Hypercholesterolaemia November 2018 TABLE OF CONTENTS Acronyms 3 Executive Summary 4 Introduction 5 Approach 5 Structure of the report 5 Economic burden of hypercholesterolaemia
More informationASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes
ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes Jane Armitage and Louise Bowman on behalf of the ASCEND
More informationApplied Medical. Statistics Using SAS. Geoff Der. Brian S. Everitt. CRC Press. Taylor Si Francis Croup. Taylor & Francis Croup, an informa business
Applied Medical Statistics Using SAS Geoff Der Brian S. Everitt CRC Press Taylor Si Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Croup, an informa business A
More informationTechnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493
Cladribine tablets for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 NICE 2018. All rights reserved. Subject to Notice
More informationContents. Version 1.0: 01/02/2010 Protocol# ISRCTN Page 1 of 7
Contents 1. INTRODUCTION... 2 2. STUDY SYNOPSIS... 2 3. STUDY OBJECTIVES... 2 3.1. Primary Objective... 2 3.2. Secondary Objectives... 2 3.3. Assessment of Objectives... 3 3.4. Change the Primary Objective
More informationCARDIOVASCULAR RISK and NSAIDs
CARDIOVASCULAR RISK and NSAIDs Dr. Syed Ghulam Mogni Mowla Assistant Professor of Medicine Shaheed Suhrawardy Medical College, Dhaka INTRODUCTION NSAIDs are most commonly prescribed drugs Recent evidence
More informationGSK Medicine: Study No.: Title: Rationale: before initiation of treatment, every 4-6 weeks during treatment
GSK Medicine: Lapatinib Study No.: WWE115270/WEUKSTV4275 Title: Assessment of Physician Compliance to Recommend Liver Function Test (LFT) Monitoring for Lapatinib Patients Rationale: Lapatinib (Tykerb
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney
More informationLearning Objectives 9/9/2013. Hypothesis Testing. Conflicts of Interest. Descriptive statistics: Numerical methods Measures of Central Tendency
Conflicts of Interest I have no conflict of interest to disclose Biostatistics Kevin M. Sowinski, Pharm.D., FCCP Last-Chance Ambulatory Care Webinar Thursday, September 5, 2013 Learning Objectives For
More informationAn Analysis of Prescribing of Methylphenidate Hydrochloride in QRESEARCH
An Analysis of Prescribing of Methylphenidate Hydrochloride in QRESEARCH An analysis using QRESEARCH for the Department of Health Authors: Professor Julia Hippisley-Cox Professor Mike Pringle Ronan Ryan
More informationSummary HTA. HTA-Report Summary
Summary HTA HTA-Report Summary Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events Schnell-Inderst
More informationAnn Rheum Dis 2017;76: doi: /annrheumdis Lin, Wan-Ting 2018/05/161
Ann Rheum Dis 2017;76:1642 1647. doi:10.1136/annrheumdis-2016-211066 Lin, Wan-Ting 2018/05/161 Introduction We and others have previously demonstrated an increased risk of acute coronary syndrome (ACS)
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationRecent developments in mortality
Recent developments in mortality Richard Willets Willets Consulting Recent developments in mortality Patterns of aggregate mortality change Underlying causes Heart disease Lung cancer Other cancers Patterns
More informationSupplementary Online Content
Supplementary Online Content Rollman BL, Herbeck Belnap B, Abebe KZ, et al. Effectiveness of online collaborative care for treating mood and anxiety disorders in primary care: a randomized clinical trial.
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationThe All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.
ENCLOSURE 5 APPENDIX 1 Paper presented to AWMSG in June 2006 AWPAG considered comments recorded in AWMSG minutes in July 2006 Paper subsequently updated and brought back to AWMSG for endorsement This paper
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationSystematic Reviews and Meta- Analysis in Kidney Transplantation
Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT
More informationDevelopment and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
open access Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study Julia Hippisley-Cox, 1 Carol Coupland, 1 Peter Brindle
More informationGOVERNING BODY REPORT
GOVERNING BODY REPORT DATE OF MEETING: 20th September 2012 TITLE OF REPORT: KEY MESSAGES: NHS West Cheshire Clinical Commissioning Group has identified heart disease as one of its six strategic clinical
More informationStudy Exposures, Outcomes:
GSK Medicine: Coreg IR, Coreg CR, and InnoPran Study No.: WWE111944/WEUSRTP3149 Title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic
More informationModular Program Report
Disclaimer The following report(s) provides findings from an FDA initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also
More informationCost-effectiveness of brief intervention and referral for smoking cessation
Cost-effectiveness of brief intervention and referral for smoking cessation Revised Draft 20 th January 2006. Steve Parrott Christine Godfrey Paul Kind Centre for Health Economics on behalf of PHRC 1 Contents
More informationAntidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database
open access Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database Carol Coupland, 1 Trevor Hill, 1 Richard Morriss,
More informationRegression Discontinuity Designs: An Approach to Causal Inference Using Observational Data
Regression Discontinuity Designs: An Approach to Causal Inference Using Observational Data Aidan O Keeffe Department of Statistical Science University College London 18th September 2014 Aidan O Keeffe
More informationNHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015)
Title of Project: NHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015) 1 Reason for the review In the UK, low dose aspirin (75mg) is licensed for the prevention of thrombotic
More informationOnline Appendices Online Appendix 1 Online Appendix 2 Online Appendix 3a Online Appendix 3b Online Appendix 3c Online Appendix 4 Online Appendix 5
Online Appendices Online Appendix 1 Search terms used to identify studies Online Appendix 2 The identification process for eligible studies Online Appendix 3a- Niacin, Risk of bias table Online Appendix
More informationSummary of 2011/12 QOF indicator changes, points and thresholds
Summary of 2011/12 QOF indicator changes, points and thresholds Retirements 2010/11 QOF ID 2010/11 Indicator Wording Points Threshold CHD5 The percentage of patients with coronary heart disease whose notes
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationUse of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
open access Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the and databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Division of
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationManaged Care Trends in Statin Usage GARY R. BAZALO, MS, MBA
PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.
More informationCORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW
CONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN CONARY ARTERY DISEASE (CAD) MEASURES GROUP: #6. Coronary Artery Disease (CAD): Antiplatelet
More informationHealth technology The use of simvastatin to reduce low-density lipoprotein (LDL) cholesterol levels.
Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Ito M K, Lin J C, Morreale A P, Marcus D B, Shabetai R, Dresselhaus T R, Henry R R Record Status This is a critical
More informationThe Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP
The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP Professor of Medicine, Endowed Chair in Patient Health Management, Health Scholar of the Alberta Heritage Foundation,
More informationIncorporating Clinical Information into the Label
ECC Population Health Group LLC expertise-driven consulting in global maternal-child health & pharmacoepidemiology Incorporating Clinical Information into the Label Labels without Categories: A Workshop
More information